Anthelmintic Drugs Market (Drug Class: Benzimidazole, Piperazine, and Others; and Route of Administration: Oral and Injectable) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
Anthelmintic Drugs Market – Scope of Report
TMR’s report on the global anthelmintic drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global anthelmintic drugs market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global anthelmintic drugs market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the anthelmintic drugs market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global anthelmintic drugs market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global anthelmintic drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global anthelmintic drugs market.
The report delves into the competitive landscape of the global anthelmintic drugs market. Key players operating in the global anthelmintic drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global anthelmintic drugs market profiled in this report.
Key Questions Answered in Global anthelmintic drugs Market Report
- What is the sales/revenue generated by anthelmintic drugs across all regions during the forecast period?
- What are the opportunities in the global anthelmintic drugs market?
- What are the major drivers, restraints, opportunities, and threats in the market?
- Which regional market is set to expand at the fastest CAGR during the forecast period?
- Which segment is expected to generate the highest revenue globally in 2031?
- Which segment is projected to expand at the highest CAGR during the forecast period?
- What are the market positions of different companies operating in the global market?
The comprehensive report on the global anthelmintic drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global anthelmintic drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global anthelmintic drugs market.
- 1. Preface
- 1.1. Market Definition and Scope
- 1.2. Market Segmentation
- 1.3. Key Research Objectives
- 1.4. Research Highlights
- 2. Assumptions and Research Methodology
- 3. Executive Summary: Global Anthelmintic Drugs Market
- 4. Market Overview
- 4.1. Introduction
- 4.1.1. Product Definition
- 4.1.2. Industry Evolution / Developments
- 4.2. Overview
- 4.3. Market Dynamics
- 4.3.1. Drivers
- 4.3.2. Restraints
- 4.3.3. Opportunities
- 4.4. Global Anthelmintic Drugs Market Analysis and Forecast, 2017–2031
- 5. Key Insights
- 5.1. Pipeline Analysis
- 5.2. Key Product/Brand Analysis
- 5.3. Key Mergers & Acquisitions
- 5.4. COVID-19 Pandemic Impact on Industry
- 6. Global Anthelmintic Drugs Market Analysis and Forecast, by Drug Class
- 6.1. Introduction and Definitions
- 6.2. Key Findings/Developments
- 6.3. Market Value Forecast, by Drug Class, 2017–2031
- 6.3.1. Benzimidazole
- 6.3.2. Piperazine
- 6.3.3. Others
- 6.4. Market Attractiveness, by Drug Class
- 7. Global Anthelmintic Drugs Market Analysis and Forecast, by Route of Administration
- 7.1. Introduction and Definitions
- 7.2. Key Findings/Developments
- 7.3. Market Value Forecast, by Route of Administration, 2017–2031
- 7.3.1. Oral
- 7.3.2. Injectable
- 7.4. Market Attractiveness, by Route of Administration
- 8. Global Anthelmintic Drugs Market Analysis and Forecast, By Application
- 8.1. Introduction and Definitions
- 8.2. Key Findings/Developments
- 8.3. Market Value Forecast, By Application, 2017–2031
- 8.3.1. Human
- 8.3.1.1. Parenchymal Neurocysticercosis
- 8.3.1.2. Gastrointestinal Infections
- 8.3.2. Animal
- 8.4. Market Attractiveness, By Application
- 9. Global Anthelmintic Drugs Market Analysis and Forecast, by Target Pathogen
- 9.1. Introduction and Definitions
- 9.2. Key Findings/Developments
- 9.3. Market Value Forecast, by Target Pathogen, 2017–2031
- 9.3.1. Ascaris Lumbricoides (Roundworm)
- 9.3.2. Trichuris Trichiura (Whipworm)
- 9.3.3. Enterobius Vermicularis (Pinworm)
- 9.3.4. Ancylostoma Duodenale (Hookworm)
- 9.3.5. Others
- 9.4. Market Attractiveness, by Target Pathogen
- 10. Global Anthelmintic Drugs Market Analysis and Forecast, by Distribution Channel
- 10.1. Introduction and Definitions
- 10.2. Key Findings/Developments
- 10.3. Market Value Forecast, by Distribution Channel, 2017–2031
- 10.3.1. Hospital Pharmacies
- 10.3.2. Retail Pharmacies
- 10.3.3. Online Pharmacies
- 10.3.4. Veterinary Pharmacies
- 10.3.5. Veterinary Hospitals & Clinics
- 10.4. Market Attractiveness, by Distribution Channel
- 11. Global Anthelmintic Drugs Market Analysis and Forecast, by Region
- 11.1. Key Findings
- 11.2. Market Value Forecast, by Region, 2017–2031
- 11.2.1. North America
- 11.2.2. Europe
- 11.2.3. Asia Pacific
- 11.2.4. Latin America
- 11.2.5. Middle East & Africa
- 11.3. Market Attractiveness, by Region
- 12. North America Anthelmintic Drugs Market Analysis and Forecast
- 12.1. Introduction
- 12.1.1. Key Findings
- 12.2. Market Value Forecast, by Drug Class, 2017–2031
- 12.2.1. Benzimidazole
- 12.2.2. Piperazine
- 12.2.3. Others
- 12.3. Market Attractiveness, by Drug Class
- 12.4. Market Value Forecast, by Route of Administration, 2017–2031
- 12.4.1. Oral
- 12.4.2. Injectable
- 12.5. Market Attractiveness, by Route of Administration
- 12.6. Market Value Forecast, By Application, 2017–2031
- 12.6.1. Human
- 12.6.1.1. Parenchymal Neurocysticercosis
- 12.6.1.2. Gastrointestinal Infections
- 12.6.2. Animal
- 12.7. Market Attractiveness, By Application
- 12.8. Market Value Forecast, by Target Pathogen, 2017–2031
- 12.8.1. Ascaris Lumbricoides (Roundworm)
- 12.8.2. Trichuris Trichiura (Whipworm)
- 12.8.3. Enterobius Vermicularis (Pinworm)
- 12.8.4. Ancylostoma Duodenale (Hookworm)
- 12.8.5. Others
- 12.9. Market Attractiveness, by Target Pathogen
- 12.10. Market Value Forecast, by Distribution Channel, 2017–2031
- 12.10.1. Hospital Pharmacies
- 12.10.2. Retail Pharmacies
- 12.10.3. Online Pharmacies
- 12.10.4. Veterinary Pharmacies
- 12.10.5. Veterinary Hospitals & Clinics
- 12.11. Market Attractiveness, by Distribution Channel
- 12.12. Market Value Forecast, by Country/Sub-region, 2017–2031
- 12.12.1. U.S.
- 12.12.2. Canada
- 12.13. Market Attractiveness Analysis
- 12.13.1. By Drug Class
- 12.13.2. By Route of Administration
- 12.13.3. By Application
- 12.13.4. By Target Pathogen
- 12.13.5. By Distribution Channel
- 12.13.6. By Country
- 13. Europe Anthelmintic Drugs Market Analysis and Forecast
- 13.1. Introduction
- 13.1.1. Key Findings
- 13.2. Market Value Forecast, by Drug Class, 2017–2031
- 13.2.1. Benzimidazole
- 13.2.2. Piperazine
- 13.2.3. Others
- 13.3. Market Attractiveness, by Drug Class
- 13.4. Market Value Forecast, by Route of Administration, 2017–2031
- 13.4.1. Oral
- 13.4.2. Injectable
- 13.5. Market Attractiveness, by Route of Administration
- 13.6. Market Value Forecast, By Application, 2017–2031
- 13.6.1. Human
- 13.6.1.1. Parenchymal Neurocysticercosis
- 13.6.1.2. Gastrointestinal Infections
- 13.6.2. Animal
- 13.7. Market Attractiveness, By Application
- 13.8. Market Value Forecast, by Target Pathogen, 2017–2031
- 13.8.1. Ascaris Lumbricoides (Roundworm)
- 13.8.2. Trichuris Trichiura (Whipworm)
- 13.8.3. Enterobius Vermicularis (Pinworm)
- 13.8.4. Ancylostoma Duodenale (Hookworm)
- 13.8.5. Others
- 13.9. Market Attractiveness, by Target Pathogen
- 13.10. Market Value Forecast, by Distribution Channel, 2017–2031
- 13.10.1. Hospital Pharmacies
- 13.10.2. Retail Pharmacies
- 13.10.3. Online Pharmacies
- 13.10.4. Veterinary Pharmacies
- 13.10.5. Veterinary Hospitals & Clinics
- 13.11. Market Attractiveness, by Distribution Channel
- 13.12. Market Value Forecast, by Country/Sub-region, 2017–2031
- 13.12.1. Germany
- 13.12.2. U.K.
- 13.12.3. France
- 13.12.4. Italy
- 13.12.5. Spain
- 13.12.6. Rest of Europe
- 13.13. Market Attractiveness Analysis
- 13.13.1. By Drug Class
- 13.13.2. By Route of Administration
- 13.13.3. By Application
- 13.13.4. By Target Pathogen
- 13.13.5. By Distribution Channel
- 13.13.6. By Country/Sub-region
- 14. Asia Pacific Anthelmintic Drugs Market Analysis and Forecast
- 14.1. Introduction
- 14.1.1. Key Findings
- 14.2. Market Value Forecast, by Drug Class, 2017–2031
- 14.2.1. Benzimidazole
- 14.2.2. Piperazine
- 14.2.3. Others
- 14.3. Market Attractiveness, by Drug Class
- 14.4. Market Value Forecast, by Route of Administration, 2017–2031
- 14.4.1. Oral
- 14.4.2. Injectable
- 14.5. Market Attractiveness, by Route of Administration
- 14.6. Market Value Forecast, By Application, 2017–2031
- 14.6.1. Human
- 14.6.1.1. Parenchymal Neurocysticercosis
- 14.6.1.2. Gastrointestinal Infections
- 14.6.2. Animal
- 14.7. Market Attractiveness, By Application
- 14.8. Market Value Forecast, by Target Pathogen, 2017–2031
- 14.8.1. Ascaris Lumbricoides (Roundworm)
- 14.8.2. Trichuris Trichiura (Whipworm)
- 14.8.3. Enterobius Vermicularis (Pinworm)
- 14.8.4. Ancylostoma Duodenale (Hookworm)
- 14.8.5. Others
- 14.9. Market Attractiveness, by Target Pathogen
- 14.10. Market Value Forecast, by Distribution Channel, 2017–2031
- 14.10.1. Hospital Pharmacies
- 14.10.2. Retail Pharmacies
- 14.10.3. Online Pharmacies
- 14.10.4. Veterinary Pharmacies
- 14.10.5. Veterinary Hospitals & Clinics
- 14.11. Market Attractiveness, by Distribution Channel
- 14.12. Market Value Forecast, by Country/Sub-region, 2017–2031
- 14.12.1. China
- 14.12.2. Japan
- 14.12.3. India
- 14.12.4. Australia & New Zealand
- 14.12.5. Rest of Asia Pacific
- 14.13. Market Attractiveness Analysis
- 14.13.1. By Drug Class
- 14.13.2. By Route of Administration
- 14.13.3. By Application
- 14.13.4. By Target Pathogen
- 14.13.5. By Distribution Channel
- 14.13.6. By Country/Sub-region
- 15. Latin America Anthelmintic Drugs Market Analysis and Forecast
- 15.1. Introduction
- 15.1.1. Key Findings
- 15.2. Market Value Forecast, by Drug Class, 2017–2031
- 15.2.1. Benzimidazole
- 15.2.2. Piperazine
- 15.2.3. Others
- 15.3. Market Attractiveness, by Drug Class
- 15.4. Market Value Forecast, by Route of Administration, 2017–2031
- 15.4.1. Oral
- 15.4.2. Injectable
- 15.5. Market Attractiveness, by Route of Administration
- 15.6. Market Value Forecast, By Application, 2017–2031
- 15.6.1. Human
- 15.6.1.1. Parenchymal Neurocysticercosis
- 15.6.1.2. Gastrointestinal Infections
- 15.6.2. Animal
- 15.7. Market Attractiveness, By Application
- 15.8. Market Value Forecast, by Target Pathogen, 2017–2031
- 15.8.1. Ascaris Lumbricoides (Roundworm)
- 15.8.2. Trichuris Trichiura (Whipworm)
- 15.8.3. Enterobius Vermicularis (Pinworm)
- 15.8.4. Ancylostoma Duodenale (Hookworm)
- 15.8.5. Others
- 15.9. Market Attractiveness, by Target Pathogen
- 15.10. Market Value Forecast, by Distribution Channel, 2017–2031
- 15.10.1. Hospital Pharmacies
- 15.10.2. Retail Pharmacies
- 15.10.3. Online Pharmacies
- 15.10.4. Veterinary Pharmacies
- 15.10.5. Veterinary Hospitals & Clinics
- 15.11. Market Attractiveness, by Distribution Channel
- 15.12. Market Value Forecast, by Country/Sub-region, 2017–2031
- 15.12.1. Brazil
- 15.12.2. Mexico
- 15.12.3. Rest of Latin America
- 15.13. Market Attractiveness Analysis
- 15.13.1. By Drug Class
- 15.13.2. By Route of Administration
- 15.13.3. By Application
- 15.13.4. By Target Pathogen
- 15.13.5. By Distribution Channel
- 15.13.6. By Country/Sub-region
- 16. Middle East & Africa Anthelmintic Drugs Market Analysis and Forecast
- 16.1. Introduction
- 16.1.1. Key Findings
- 16.2. Market Value Forecast, by Drug Class, 2017–2031
- 16.2.1. Benzimidazole
- 16.2.2. Piperazine
- 16.2.3. Others
- 16.3. Market Attractiveness, by Drug Class
- 16.4. Market Value Forecast, by Route of Administration, 2017–2031
- 16.4.1. Oral
- 16.4.2. Injectable
- 16.5. Market Attractiveness, by Route of Administration
- 16.6. Market Value Forecast, By Application, 2017–2031
- 16.6.1. Human
- 16.6.1.1. Parenchymal Neurocysticercosis
- 16.6.1.2. Gastrointestinal Infections
- 16.6.2. Animal
- 16.7. Market Attractiveness, By Application
- 16.8. Market Value Forecast, by Target Pathogen, 2017–2031
- 16.8.1. Ascaris Lumbricoides (Roundworm)
- 16.8.2. Trichuris Trichiura (Whipworm)
- 16.8.3. Enterobius Vermicularis (Pinworm)
- 16.8.4. Ancylostoma Duodenale (Hookworm)
- 16.8.5. Others
- 16.9. Market Attractiveness, by Target Pathogen
- 16.10. Market Value Forecast, by Distribution Channel, 2017–2031
- 16.10.1. Hospital Pharmacies
- 16.10.2. Retail Pharmacies
- 16.10.3. Online Pharmacies
- 16.10.4. Veterinary Pharmacies
- 16.10.5. Veterinary Hospitals & Clinics
- 16.11. Market Attractiveness, by Distribution Channel
- 16.12. Market Value Forecast, by Country/Sub-region, 2017–2031
- 16.12.1. GCC Countries
- 16.12.2. South Africa
- 16.12.3. Rest of Middle East & Africa
- 16.13. Market Attractiveness Analysis
- 16.13.1. By Drug Class
- 16.13.2. By Route of Administration
- 16.13.3. By Application
- 16.13.4. By Target Pathogen
- 16.13.5. By Distribution Channel
- 16.13.6. By Country/Sub-region
- 17. Competition Landscape
- 17.1. Market Player – Competition Matrix (By Tier and Size of Companies)
- 17.2. Market Share Analysis, by Company (2022)
- 17.3. Company Profiles
- 17.3.1. Novartis AG
- 17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.1.2. Product Portfolio
- 17.3.1.3. Financial Overview
- 17.3.1.4. SWOT Analysis
- 17.3.1.5. Strategic Overview
- 17.3.2. Zoetis, Inc.
- 17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.2.2. Product Portfolio
- 17.3.2.3. Financial Overview
- 17.3.2.4. SWOT Analysis
- 17.3.2.5. Strategic Overview
- 17.3.3. Amneal Pharmaceuticals, Inc.
- 17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.3.2. Product Portfolio
- 17.3.3.3. Financial Overview
- 17.3.3.4. SWOT Analysis
- 17.3.3.5. Strategic Overview
- 17.3.4. Cipla Inc.
- 17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.4.2. Product Portfolio
- 17.3.4.3. Financial Overview
- 17.3.4.4. SWOT Analysis
- 17.3.4.5. Strategic Overview
- 17.3.5. Janssen Pharmaceuticals, Inc. (Johnson & Johnson)
- 17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.5.2. Product Portfolio
- 17.3.5.3. Financial Overview
- 17.3.5.4. SWOT Analysis
- 17.3.5.5. Strategic Overview
- 17.3.6. Sun Pharmaceutical Industries Ltd.
- 17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.6.2. Product Portfolio
- 17.3.6.3. Financial Overview
- 17.3.6.4. SWOT Analysis
- 17.3.6.5. Strategic Overview
- 17.3.7. GlaxoSmithKline plc
- 17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.7.2. Product Portfolio
- 17.3.7.3. Financial Overview
- 17.3.7.4. SWOT Analysis
- 17.3.7.5. Strategic Overview
- 17.3.8. Bayer AG
- 17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.8.2. Product Portfolio
- 17.3.8.3. Financial Overview
- 17.3.8.4. SWOT Analysis
- 17.3.8.5. Strategic Overview
- 17.3.9. Merck & Co. Inc. (Intervet Inc.)
- 17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.9.2. Product Portfolio
- 17.3.9.3. Financial Overview
- 17.3.9.4. SWOT Analysis
- 17.3.9.5. Strategic Overview
- 17.3.10. Boehringer Ingelheim International GmbH
- 17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
- 17.3.10.2. Product Portfolio
- 17.3.10.3. Financial Overview
- 17.3.10.4. SWOT Analysis
- 17.3.10.5. Strategic Overview
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook